Neonatal Screening for Cystic Fibrosis (NS CF) has been introduced in the Czech Republic (CR) since October 2009. For the Moravia region, CF Center of University Hospital Brno performs examinations (IRT/DNA analysis and comprehensive care for patients with 1 and/or 2 mutations in the CFTR gene). Every year we examine IRT level from dry blood spot in around 40,000 newborns, a positive result and DNA analysis of 50 CFTR mutations (Elucigene) is indicated in about 1% of newborns and in about 1% of the analyzes we confirm the newborn with CF. As part of comprehensive care for families of newborns with one and/or two mutations in the CFTR gene, we noted certain facts, that we further analyzed: -Lower prevalence of CF in the study population compared to the statistics. Conclusions: NS CF in CR definitely met expectations and leads to early detection of CF patients. NS CF but also brings some unexpected findings and situations to be applied within the comprehensive care and genetic counseling. Detection of patients with CF with NS is not 100%. Detection of heterozygotes is irrelevant − unsolicited finding that brings stress situations, but also allows the family genetic counseling and targeted CF prevention. Efforts to minimize the psychological stress of parents will never be completely successful. Objectives: To assess the diagnostic and clinical outcomes of infants in their first year of life, followed up after cystic fibrosis newborn screening (NS). Methods: A transversal and descriptive study including 24 infants followed up from 2010-2012 that were screened by immunoreactive trypsinogen (IRT) tests in 2 measurements in the first month of age with the cut-off value 70 ng/ml and positive sweat chloride test (SCT). The clinical outcomes were assessed in the months 0, 3, 6, 9, 12. All received similar treatment. Among 24 infants: 16 were male and 21 Caucasian. 3 died. IRT was realized during the first week and in the 3rd or 4rt week of life. The mean values were: IRT1 = 191 ng/ml and IRT2=207 ng/ml. The mean values of SCT were100.3 and 110 mEq/l. 90% presented respiratory manifestations and 33.33% had pulmonary colonization by P. aeruginosa. All 24 patients had digestive manifestations with 21% of steatocrit mean values. In the first month of life, 16.66% and 12.5% of them had already been hospitalized for respiratory disorders and meconium ileus respectively. The most critical clinical health condition happened between 3 and 6 months of life, in which 45.83% were hospitalized (20.83% and 25% with metabolic and respiratory disorders). In the evaluation of 0, 3 and 6 months of life all infants presented one or more of: diarrhea, malnutrition, weight percentile <3, persistent cough, dehydration and pulmonary exacerbations. No patient had the characteristics mentioned above at the age of 9 and 12 months.
Conclusion:
The NS contributed for a good nutritional status, improvement of metabolic and respiratory conditions and lack of hospitalizations after 6 months of age. In 16 (9.8%) children none of the two sweat tests could be performed at the first assessment. Sensitivity and specificity data will be presented at the conference when all investigation details will be available.
Conclusions:
In this pilot study, Nanoduct showed a better feasibility for use in newborns compared to the Macroduct, mainly because it needs a lower sweat volume.
